Browsing Tag
PROTECT Study
3 posts
Sanofi (SNY) wins a pivotal Tzield label expansion into recently diagnosed stage 3 type 1 diabetes
Sanofi (SNY) wins FDA accelerated approval for Tzield in recently diagnosed stage 3 type 1 diabetes, expanding its market beyond screening. Full analysis here.
FILSPARI secures full European approval: A major breakthrough for IgA nephropathy patients
Find out how FILSPARI’s full EU approval marks a major step for IgA nephropathy treatment and strengthens CSL Vifor and Travere Therapeutics’ rare disease focus.
Primary IgA nephropathy : FDA grants full approval to Travere Therapeutics’ Filspari
In a groundbreaking move, the US Food and Drug Administration (FDA) has granted full approval to Travere Therapeutics’…